Literature DB >> 433621

The determination of naproxen by spectrofluorometry and its binding to serum proteins.

A Mortensen, E B Jensen, P B Petersen, S Husted, F Andreasen.   

Abstract

A fluorometric method for the determination of naproxen in serum, albumin solutions and protein free buffer solutions is described. The detection limit is about 10 ng/ml. Furosemide, thiopental and salicylic acid did not show any disturbing fluorescence while phenprocoumon did. The in vitro binding of naproxen in albumin solutions and serum was studied by equilibrium dialysis. A small but significant increase was found in the percentual binding in albumin solutions as compared to serum. The percentual binding was not affected by changes in the pH from 5--8. By fitting the binding data to a model assuming two classes of binding sites, association constants and binding capacities were determined. A very high affinity and a high capacity were found. The association constant for the first class of binding sites was higher for human serum albumin than for serum (8.5 versus 5.3 . 10(6) M-1). The difference in the protein binding to the first class of binding sites in human serum albumin and serum can be explained by the existence of a competitive inhibitor in serum.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 433621     DOI: 10.1111/j.1600-0773.1979.tb02330.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  10 in total

Review 1.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

2.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

3.  Stereoselective binding properties of naproxen glucuronide diastereomers to proteins.

Authors:  A Bischer; P Zia-Amirhosseini; M Iwaki; A F McDonagh; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

4.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

5.  Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

Review 6.  Clinical pharmacokinetics of naproxen.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

7.  Free plasma concentrations of piroxicam in patients with osteoarthritis: relation to age, sex and efficacy.

Authors:  O Hundal; H E Rugstad
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

8.  The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine.

Authors:  T B Vree; M Van Den Biggelaar-Martea; C P Verwey-Van Wissen; M L Vree; P J Guelen
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

9.  Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.

Authors:  P Bertin; F Lapicque; E Payan; M Rigaud; F Bailleul; S Jaeger; R Treves; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro.

Authors:  Harald Olsen; Anders Andersen; Arve Nordbø; Ulf E Kongsgaard; Ole P Børmer
Journal:  BMC Clin Pharmacol       Date:  2004-03-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.